Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis

Abstract

BackgroundAsthma is a common respiratory disease, which may be associated with an increased risk of herpes zoster (HZ), often a debilitating disease associated with severe pain. This is the first systematic review with the objective of summarising evidence on HZ burden in adults with asthma.MethodsA global systematic literature review and meta-analysis was conducted (MEDLINE and Embase, 2003–2024) on HZ burden (incidence, risk and complications) in adults (≥18 years) with asthma.ResultsThere were 19 studies included on HZ outcomes in adults with asthma. Pooled HZ incidence per 1000 person-years was 5.71 (95% CI 4.68–6.96) in adults aged ≥18 years (4.20 (95% CI 3.09–5.70) in those aged <60 yearsversus10.33 (95% CI 9.17–11.64) in those aged ≥60 years). The pooled rate ratio for developing HZ was 1.23 (95% CI 1.11–1.35) in those aged ≥18 years and 1.36 (95% CI 1.15–1.61) in those aged ≥50 years. The risk of HZ was higher in people with asthma using systemic corticosteroids, long-acting β-agonists plus inhaled corticosteroids and “add-on therapy”. Asthma was also associated with an increased risk of post-herpetic neuralgia (OR 1.21, 95% CI 1.06–1.37) and HZ ophthalmicus (OR 1.9, 95% CI 1.1–3.2). Differences in study design, setting, case definitions and follow-up durations led to heterogeneity.ConclusionsThis systematic literature review and meta-analysis found that adults with asthma have an increased risk of HZ, with higher risks in older age groups and in those on certain treatments, such as oral corticosteroids. HZ vaccines are available for adults, including those with comorbidities such as asthma, and can be considered as part of integrated respiratory care.